Nuevos conceptos en el tratamiento antibiótico en farmacocinética y farmacodinamia (Pk/PD)nuevos antibióticos

Referencias bibliográficas

• Clinical Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing;15th informational supplement. NCCLS Document M100-S15. CLSI, Wayne PA. USA 2005.
• Drusano GL, Craig WA. Relevancia de la farmacocinética y farmacodinámica en la selección de antibióticos para infecciones del tracto respiratorio. Enf Infecc y Micro 2000; 20(5): 191-197.
• World Health Organization. World Health Organitation report on infectious diseases 2000: Overcoming antimicrobial resistence. Available at: http://www.who.int/infectious-diseasereport/2000/intro.htm.
• Aguado-García JM, Martin-Herrero JE, Lumbreras-Bermejo C. Resistencias bacterianas y farmacodinamia como bases de la prescripción de antibióticos en infecciones respiratorias. Enferm Infecc Microbiol Clin 2004; 22: 230-237.
• Soriano F. Aspectos farmacocinéticos y farmacodinámicos para la lectura interpretada del antibiograma. Enferm Infecc Microbiol Clin 2002; 20:407-411.
• Stass H, Dalhoff A. The integrated use of pharmacokinetic and pharmacodynamic models for the definition of breakpoints. Infection 2005;33 (Suppl,2):29-35.
• Soriano F. Importancia de los parámetros farmacocinéticos y farmacodinámicos en la elección del tratamiento antimicrobiano de la infección respiratoria. Med Clin (Barc) 2004; 5: 6-11.
• Eiros Bouza JM, Valdés Verlest L, Bachiller Luque MR. Contribución de la farmacodinamia en la elección del antimicrobiano para las exacerbaciones de la EPOC. Rev Esp Quimioterap 2006; 19(3): 220-230.
• Grupo de estudio de la neumonía adquirida en la comunidad. Área TIR-SEPAR. Normativas para el diagnóstico y el tratamiento de la neumonía adquirida en la comunidad. Sociedad Española de Neumología y Cirugía Torácica (SEPAR). Arch Bronconeumol 2005; 41: 272-289.
• Boughman RP, Pina E. Infections in acute exacerbations of chronic bronchitis: what are the and how do we know? Sem Resp Crit Care Med 2000; 21: 87-96.
• DeRyke CA, Lee SY, Kuti JL, Nicolau DP. Optimising dosing strategies of antibacterials utilising pharmacodynamic principles: impact on the development of resistance. Drugs 2006; 66: 1-14.
• Pérez-Trallero E, Garcia de la Fuente C, García-Rey C, et al.. Spanish Surveillance Group for Respiratory Pathogens. Geographical and ecological analysis of resistance, coresistance and coupled resistance to antimicrobials in respiratory pathogenic bacteria in Spain. Antimicrob Agents Chemother 2005; 49: 1965-1972.
• Giménez MJ, Gómez-Lus ML, Valdés L, Aguilar L. Situación de la cefalosporina oral de tercera generación cefditoreno pivoxil en el tratamiento de la infección comunitaria del adulto. Rev Esp Quimioterap 2005; 18 (3): 210-216.
• Soriano F, Granizo JJ, Coronel P, et al. Antimicrobial susceptibility of Haemophilus influenzae, Haemophilus parainfluenzae and Moraxella catarrhalis isolated from adult patients with respiratory tract infections in four southern European countries. The ARISE project. Int J Antimicrob Agents 2004; 23: 296-299.
• Soriano F, Granizo JJ, Fenoll A, et al. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae isolated in four Southern European countries (ARISE Project) from adult patients: Results from the Cefditoren Surveillance Program. J Chemother 2003; 15: 107-112.
• Clark CL, Nagai K, Dewasse BE, et al. Activity of cefditoren against respiratory pathogens. J Antimicrob Chemother 2002; 50: 33-41.
• Kaye CM, Allen A, Perry S, Mc Donagh M, Davy M, Storm K et al. The clinical pharmacokinetics of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate. Clin Ther 2001; 23: 578-584.
• Aguilar L, Gimenez MJ, García-Rey C, Martín JE. Strategies to overcome antimicrobial resistance in Streptococcus pneumoniae with beta-lactam antibiotics. J Antimicrob Chemother 2002; 50 (suppl S2): 93-100.
• Loza E, Morosini MI, Cantón R, Almaraz F, Reig M, Baquero F. Actividad comparativa in vitro de ertapenem frente a bacterias aerobias y anaerobias. Rev Esp Quimioterap 2003; 16: 209-215.
• Gobernado M, Acuña C. Ertapenem. Rev Esp Quimioterap 2007; 20: 277-299.
• Rodríguez-Baño J, Navarro MD, Romero L, et al. Epidemiology and clinical features of infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in nonhospitalized patients. J Clin Microbiol 2004; 42: 1089-1094.
• Ortiz-Ruiz G, Caballero-López J, Friedland IR, Woods GL, Carides A, Protocol 018 Ertapenem Community-Acquired Pneumonia Study Group. A study evaluating the efficacy, safety, and tolerability of ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults. Clin Infect Dis 2002; 34: 1076-1083.
• Vetter N, Cambronero-Hernández E, Rohlf J, et al. Protocol 020 Study Group. A prospective, randomized, double-blind multicenter comparison of parenteral ertapenem and ceftriaxone for the treatment of hospitalized adults with community-acquired pneumonia. Clin Ther 2002; 24: 1770-1785.
• File TM. Telithromycin new product overview. J Allergy Clin Inmunol 2005; 115: S1-13.
• Clay KD, Hanson JS, Pope SD, Rissmiller RW, Purdum PP, Banks PM. Brief communication: severe hepatotoxicity of telithromycin: three case reports and literature review. Ann Intern Med 2006; 144: 415-420.
• Willcox M. Efficacy of linezolid versus comparator therapies in gram-positive infections. J Antimicrob Chemother 2003; 51 (Suppl S2): ii27-ii35.
• Girón-Moreno RM, Ruiz-Velasco LM, Buendía V. Utilidad del linezolid en la fibrosis quística. Enferm Infecc Microbiol Clin 2004; 22: 369-370.
• Nadler H, Dowzicky MJ, Feger C, Pease MR, Prokocimer P. Quinupristin/dalfopristin: a novel selective-spectrum antibiotic for the treatment of multi-resistant and other gram-positive pathogens. Clin Microbiol Newslett 1999; 21: 103-112.
• Wilson P. Endemic, highly resistant Acinetobacter in the intensive care unit. Is tigecycline the answer? Clin Microbiol Infect 2004; 10 (Suppl 3): 247.
• Zhanel GG, Lam A, Schweizer F, Thomson K, Walkty A, Rubinstein E, Gin AS, Hoban DJ, Noreddin AM, Karlowsky JA. Ceftobiprole: a review of a broad-spectrum and anti-MRSA cephalosporin. Am J Clin Dermatol. 2008;9(4):245-54.
• Peppard WJ, Schuenke CD. Iclaprim, a diaminopyrimidine dihydrofolate reductase inhibitor for the potential treatment of antibiotic-resistant staphylococcal infections. Curr Opin Investig Drugs 2008; 9(2): 210-25.
• Francis JS, Doherty MC, Lopain U, Johnston CP, Sinha G, Ross T, Cai M, Hansel NN, Perl T, et al. Severe community-onset pneumonia in healthy adults caused by methicilin resistant Staphylococcus aureus carryng the Panton-Valentine leukocidin genes. Clin Infect Dis 2005; 40: 100-107.
• Bethel CR, Distler AM, Rusczycky MV, Carey MP, Carey RR, Hujer AM, et al. Inhibition of OXAM-1beta-lactamase by penems. Antimicrob Agents Chemoter 2008; 52 (9): 3135-43.
• Tillotson CJ. Role de gemifloxacin in community–adquired pneumonia. Expert Rev Anti infect Ther 2008, 6(4): 405-18.
• Blasi F, Alberti S, Tarsia P, Santus P, Centanni S, Allegra L. Plurifloxacin. A brief review in the treatment of acute exacerbation of chronic bronchitis. Int J Chron Obstruct Pulmon Dis 2007; 2 (1): 27-31.
• Park-Wyllie LY, Juurlink DN, Kopp A, Shah BR, Stukel TA, Stumpo C, Dresser L, Low DE, Mamdani MM. Outpatient gatifloxacin therapy and dysglycemia in older adults. N Engl J Med 2006; 354:1352-1361.
• Dale KM, Lertsburapa K, kluger J, Whitw CM. Moxifloxacin and torsade de pointes. Ann Pharmacother 2007; 41(2): 336-40.
• Morganroth J, Dimarco JP, Anzueto A, Niederman MS, Choudhri S. CAPRIE Study group. A randomized trial comparing the cardiac rhythm safety of moxifloxacin vs levofloxacin in elderly patients hospitalized whit community-acquired pneumonia. Chest 2005; 128: 3398-3406.
• Hammerschlag MR, Sharma R. Use of cethromycin, a new ketolide, for treatment of community-acquired respiratory infections. Expert Opin Investig Drugs 2008; 17 (3): 387-400.
• Kosowska-Shick K, Clark C, Credito K, Dewasse B, Beachel L, Ednie L, Appelbaum PC.In vitro capability of faropenem to select for resistant mutants of Streptococcus pneumoniae and Haemophilus influenzae. Antimicrob Agents Chemother 2008 Feb;52 (2):748-52.
• Sawa T, Vallis A, Snack E, Frank DW, Wiener-kronish JP. Development and characterization of monoclonal antibody to pseudomonas aeruginosa type III secreted protein PcrV. Abstr Interstici Conf Antimicrob Agents Chemother Interstici 2001 (41):16-19 (nº B-997).
• Pérez-Dorado I, Campillo NE, Monterroso B, Hesek D, Lee M, Páez JA, García P, et al. Elucidation of the Molecular Recognition of Bacterial Cell Wall by Modular Pneumococcal Phage Endolysin CPL-1. J. Biol. Chem., Vol. 282, Issue 34, 24990-24999, August 24, 2007.
• Kollef M, Pittet D, Sánchez-García M, Chastre J, Fagon JY, et al, for the Prevention of Pneumonia Study (POPS-1) Trial Group. A Randomized Double-Blind Trial of Iseganan in Prevention of Ventilator-associated Pneumonia. Am J Respir Crit Care Med 2006; 173: 91-97.